Výsledky vyhledávání - "Ipek Ozer Stillman"

Akademický článek

Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements

Autor: Jeffrey M. Muir, Amruta Radhakrishnan, Andreas Freitag, Ipek Ozer Stillman, Grammati Sarri

Publikováno v: Frontiers in Pharmacology, Vol 14 (2023)

Health technology assessment (HTA) has traditionally relied on cost-effectiveness analysis (CEA) as a cornerstone of evaluation of new therapies, assessing the clinical validity and utility, the efficacy, and the cost-effectiveness of new interventio

Externí odkaz: https://doaj.org/article/3e43e21f0ebb4669ba58d98d49caea1f

Zobrazit plný text záznamu

A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction

Autor: Mustafa Oguz, Ipek Ozer-Stillman, Glenn Davies, Mark Du, Lori D. Bash, J. Whalen

Publikováno v: American journal of cardiovascular drugs : drugs, devices, and other interventions. 16(4)

The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed262fe822e9a7fee89df21978397e1c
https://pubmed.ncbi.nlm.nih.gov/27262432

Zobrazit plný text záznamu

Abstract 372: Health Outcomes Associated With Triple Antiplatelet Therapy for the Secondary Prevention of Atherothrombotic Events

Autor: J. Whalen, Mark Du, Mustafa Oguz, Ipek Ozer-Stillman, Lori D. Bash, Puneet K. Singhal, Glenn Davies

Publikováno v: Circulation: Cardiovascular Quality and Outcomes. 8

Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of atherothrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD), based on th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50499670f709f1605485057bc4c5be43
https://doi.org/10.1161/circoutcomes.8.suppl_2.372

Zobrazit plný text záznamu

Cost-Effectiveness Analysis (CEA) of Sequential Treatment with Tyrosine Kinase Inhibitors (TKIs) for Chronic Myelogenous Leukemia (CML)

Autor: Ipek Ozer Stillman, J. Whalen, Bjorn Bolinder, Dinara Makenbaeva, Eugene Felber, Apoorva Ambavane

Publikováno v: Blood. 124:2607-2607

Background: Imatinib has been approved for treatment of newly diagnosed CML since 2001. For patients failing imatinib, other treatment options such as dasatinib, nilotinib, bosutinib, and high-dose imatinib are recommended. Previous economic analyses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3edeec3651ebcf91475533d7b049dd27
https://doi.org/10.1182/blood.v124.21.2607.2607

Zobrazit plný text záznamu

The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST)

Autor: Ateesha F. Mohamed, Katherine E. Tranbarger Freier, Lauren N. Strand, Jane Chang, Kyle Fahrbach, Ipek Ozer Stillman

Publikováno v: Journal of Clinical Oncology. 32:10557-10557

10557 Background: OS is the gold-standard measure of treatment efficacy in cancer. However, PFS is often used as primary endpoint when OS follow-up is long and/or post-progression therapy is common...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f5df98467a3209114adfd53322ef09c
https://doi.org/10.1200/jco.2014.32.15_suppl.10557

Zobrazit plný text záznamu

An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US)

Autor: Paul Cislo, Ipek Ozer-Stillman, Apoorva Ambavane

Publikováno v: Journal of Clinical Oncology. 31:e15601-e15601

e15601 Background: Cytokines are a first-line treatment option for a subset of advanced RCC patients in the US. After progression on cytokines, NCCN guidelines recommend targeted agents, such as axitinib and sorafenib. Subgroup analysis of post-cytok

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7868ac4da64dbe5cd7a2bb28764de1a7
https://doi.org/10.1200/jco.2013.31.15_suppl.e15601

Zobrazit plný text záznamu

Cost-effectiveness of regorafenib for pretreated metastatic colorectal cancer patients in the United States

Autor: Ipek Ozer-Stillman, Brian S. Seal, Vivek Pawar, J. Whalen, Avin Yaldo, Apoorva Ambavane

Publikováno v: Journal of Clinical Oncology. 31:578-578

578 Background: There is an unmet need for treatments that provide a survival benefit for patients with heavily pretreated metastatic colorectal cancer (mCRC). In a randomized, double-blind, placebo-controlled trial, patients treated with regorafenib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3b3273e4d78f8075ecce208f9fa8cea
https://doi.org/10.1200/jco.2013.31.4_suppl.578

Zobrazit plný text záznamu

Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL)

Autor: Ipek Ozer Stillman, Wayne Su, Gayatri Ranganathan, Peter Quon, Samantha Wronski, Christopher G. Salvador, Mkaya Mwamburi, Ananth Kadambi, Kevin B. Knopf, J. Whalen, James A. Sterchele

Publikováno v: Journal of Clinical Oncology. 30:6553-6553

6553 Background: To assess the cost-effectiveness of bendamustine plus rituximab (B-R) vs cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP‑R) for treatment-naive patients with MCL or IL from a US healthcare payer perspect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3c2aca1f6a4372822ee527cf1641481
https://doi.org/10.1200/jco.2012.30.15_suppl.6553

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání